Our results suggest that MMP9 may offer a target for anti-metastatic therapies for basal-like triple negative breast cancers, a poor prognosis subtype with few available molecularly targeted therapeutic options. This evidence concerns the gene MMP9 and triple-negative breast carcinoma.